3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
3
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Neoplasm Metastasis
5
Prostatic Neoplasms
4
Sarcoma
3
Neoplasms
3
Pancreatic Neoplasms
2
Neuroblastoma
2
Hodgkin Disease
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Urologic Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Soft Tissue Neoplasms
1
Recurrent Uterine Sarcoma
1
Recurrence
1
Pharyngeal Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neurofibromatosis 2
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Mesothelial
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphangioleiomyomatosis
1
Liver Neoplasms
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Accelerated Phase
1
Interventions
Irinotecan
58
Bevacizumab
56
Oxaliplatin
49
Leucovorin
49
Fluorouracil
49
Capecitabine
45
Cetuximab
44
pembrolizumab
23
IFL protocol
15
Nivolumab
11
regorafenib
10
Panitumumab
10
Celecoxib
8
Radiotherapy
7
Cyclophosphamide
7
atezolizumab
6
Surgical Procedures, Operative
6
Gemcitabine
6
Folfox protocol
6
Colonoscopy
6
trifluridine tipiracil drug combination
5
Neoadjuvant Therapy
5
Metformin
5
Immunohistochemistry
5
Biopsy
5
tislelizumab
4
spartalizumab
4
durvalumab
4
Trastuzumab
4
Mitomycin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Colorectal Neoplasms
×
temsirolimus
×
Clear all
NCT02423954
2018-07-02
NivoPlus
Western Regional Medical Center
Phase 1/2
Terminated
33 enrolled